Donor white blood cells to treat solid tumors
Part of Immune system & allergy clinical trials.
This Phase 1/2 study tests whether donated white blood cells (granulocytes) from healthy donors can help treat solid cancers that cannot be cured or have stopped responding to standard treatments. The goal is to see safety first, and then whether the treatment can shrink or control tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign a study consent form
- You have a solid cancer (not a blood cancer) that is metastatic or cannot be removed, and standard treatments no longer work (or do not exist)
- Your cancer has at least one measurable spot on imaging (about 2 cm on a standard scan, or about 1 cm on a spiral CT)
- You should have at least 4 months of expected life left, based on the study doctor’s judgment
- You must be well enough to participate (ECOG performance status 0–2) and be at least 4 weeks since chemo, radiation, or surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
This early-phase trial tests a new type of cell therapy using donor immune cells (called CAR-γδT cells) that are engineered to attack a protein called B7H3 found on many solid tumors. The goal is to see if this treatment is safe and could help people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new way to take blood from patients with solid tumors or healthy volunteers, grow immune cells in a lab, and then give them back to potentially treat cancer. It may help people whose standard options have run out.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This study tests a better way to collect white blood cells from healthy people who donate blood. It may help improve how reliably and safely white blood cells are collected for research or future treatments.
This early-phase study tests immune cells given from a matched donor to treat advanced non-small-cell lung cancer. It aims to see how safe the treatment is and whether it can help control the cancer.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.